Hopkins Researchers Find Drug May Help Cystic Fibrosis Patients
A study led by Johns Hopkins Researchers found that a drug, sodium 4-phenylbutyrate (4PBA), may help cystic fibrosis patients with the deltaF508 mutation by allowing more CFTR proteins to reach cell surfaces. This phenomenon occurs at concentrations normally seen in patients taking the drug for urea cycle disorders.